Stock Analysis
Bristol-Myers Squibb Co.BMY
P/E 13.15×· 5Y range 12.04–27.71×· bottom 12% of history
Sector: Healthcare · Industry: Drug Manufacturers - General
AnalystsHold35 analystsP/E 13.1× sits at the 12th percentile of its 5.089664613278576-year history.
Cash covers 24% of debt · FY 2025.
PMP Verdict
Strong business, attractive price
Strengths
- Quality95
- Profitability90
Risks
- Growth43
High-quality business at an attractive price.
Bull Case
- ✓Piotroski F-Score 8/9 — high earnings quality
- ✓ROE 50.2% — efficient capital deployment
- ✓Interest coverage 9.5× — debt well covered
- ✓P/E 13.1× at bottom 12% of 5-year history
What's happening with BMY
Profile
Strong earnings quality, valuation and profitability; growth lags behind.
How is each axis scored?
- Valuation90/100 · Strong
- P/E vs own history (12th pct)25/25
- FCF yield (9.3%)25/25
- P/S (2.5x)20/25
- EV/EBIT (12.3x)20/25
- Growth43/100 · Weak
- Revenue CAGR (1.0%)6/25
- Net income CAGR (0.2%)6/25
- EPS CAGR 5Y (2.6%)6/25
- Fwd implied growth (41.8%)25/25
- Profitability90/100 · Strong
- ROIC (19.2%)20/25
- ROE (50.2%)25/25
- Net margin (18.9%)20/25
- Operating margin (26.1%)25/25
- Financial Health53/100 · Moderate
- Altman Z (2.25)18/25
- Current ratio (1.26)12/25
- Interest coverage (9.5x)18/25
- Net cash / debt (D/A 38%)5/25
- Quality95/100 · Strong
- Piotroski F (8/9)25/25
- Beneish M (-2.85)25/25
- FCF conversion (123%)25/25
- Margin stability (σ 6.2%)20/25
- Moat63/100 · Moderate
- ROIC >12% years (6/10 yrs)13/25
- Median gross margin (71.7%)25/25
- FCF-positive years (10/10 yrs)25/25
- Worst-year net margin (worst -21.2%)0/25
Risk Flags
- ⚠2 loss-making years in recent history
About Bristol-Myers Squibb Co.
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. Show more
A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
Headquarters: PRINCETON, NJ · Employees: 32,500 · Website ↗
Price History
Weekly Candlestick Chart — up to 5Y
Key Metrics
Financial snapshot · Tap any metric for its definition and grade
TTM Snapshot
trailing twelve months · YoYValuation
90A+P/E (TTM)13.2xA
Grade A: CheapPrice / TTM EPS (own statements) — vs own 5Y history: 12.0x–27.7x · 12th pct
P/FCF7.5xA
Grade A: CheapPrice / Free Cash Flow per share (Finnhub). Inverse of FCF yield — negative when FCF is negative
FCF Yield9.3%A
Grade A: ValueTTM (OCF − CapEx) / Market Cap — vs own 5Y history: 7.3%–17.6% · 34th pct
P/S (TTM)2.50xB
Grade B: FairPrice / TTM Revenue (own statements) — vs own 5Y history: 1.7x–3.7x · 45th pct
EV/EBIT12.3xB
Grade B: FairEnterprise value / TTM EBIT (D&A not in our data) — capital-structure neutral — vs own 5Y history: 10.3x–167.9x · 26th pct
EV/Sales3.3xB
Grade B: FairEnterprise Value / TTM Revenue (Finnhub) — capital-structure neutral sales multiple
Forward P/E9.3xA
Grade A: CheapPrice / next-year EPS estimate — shows whether the TTM multiple is rich or just front-loading growth
P/B Ratio6.66xC
Grade C: ExpensivePrice to Book Value. Neg. equity = heavy buybacks
PEG Ratio-7.62A
Grade A: CheapFinnhub PEG — their P/E basis ÷ expected EPS growth. Suppressed when their P/E diverges >2× from our TTM P/E (different basis)
Dividend Yield6.04%C
Grade C: HighTTM dividend yield (Finnhub) — annual dividends / price. None = no dividend; very high yield can signal distress
Payout Ratio81.7%C
Grade C: HighDividends / Net Income (Finnhub) — share of earnings paid out; >90% or negative = unsustainable
Profitability
90A+ROIC19.2%A
Grade A: MoatNOPAT (EBIT less ~21% tax) / invested capital (equity + debt − cash). Flagship quality metric — durable >15% signals a moat
ROE50.2%A
Grade A: StrongReturn on Equity. Neg. equity = heavy buybacks
ROA10.3%A
Grade A: StrongReturn on Assets (Finnhub) — Net Income / Total Assets; how efficiently assets produce profit
Net Margin18.9%A
Grade A: HighNet Income / Revenue
Operating Margin26.1%A
Grade A: HighTTM EBIT / TTM Revenue
Gross Margin70.2%A
Grade A: PremiumGross Profit / Revenue
FCF Margin23.3%A
Grade A: HighFCF / Revenue
True FCF Margin22.1%A
Grade A: HighTTM (OCF − CapEx − SBC) / TTM Revenue — SBC treated as a real cost
Growth
43D+Revenue CAGR1.0%D
Grade D: LowCompound annual revenue growth (up to 5Y depending on data availability)
Net Income CAGR0.2%D
Grade D: LowCompound annual net income growth (up to 5Y depending on data availability)
EPS CAGR (5Y)2.6%D
Grade D: LowCompound annual EPS growth over up to 5Y of per-share earnings (own statements). Null when either endpoint EPS ≤ 0
Implied EPS Growth41.8%A
Grade A: HighAnalyst forward EPS (normalized basis) vs our GAAP TTM EPS — different bases, so extreme values usually mark cyclically depressed TTM earnings, not real growth
Dilution (5Y)-9.7%A
Grade A: BuybacksShare count change over 5Y
SBC / Net Income6.0%A
Grade A: LowStock-based comp/Net income. >30% = dilution risk
SBC / Revenue1.1%A
Grade A: LowTTM stock-based comp / TTM Revenue
Financial Health
53CAltman Z-Score2.25C
Grade C: Gray zoneBankruptcy risk. >3 Safe, <1.8 Distress
Current Ratio1.26xC
Grade C: OkCurrent Assets/Liabilities
Quick Ratio1.39xA
Grade A: High(Current Assets − Inventory) / Current Liabilities (Finnhub) — stricter liquidity test, excludes inventory
Interest Coverage9.5xC
Grade C: OkEBIT/Interest. >10 Strong
Debt Repayment3.0yC
Grade C: AverageYears to repay net debt via FCF
Net Debt/EBIT2.7xC
Grade C: MedLeverage. <2x Low, >4x High
Debt/Equity2.44xD
Grade D: HighDebt / Equity: <1 Conservative, >2 Risky. Not meaningful with non-positive equity; shown as unavailable rather than low debt.
Cash / Debt0.24xD
Grade D: ThinCash covers how much of total debt. >1 = could repay all debt from cash
Quality
95A+Piotroski F-Score8/9A
Grade A: StrongFinancial strength 0–9. >7 Strong
Beneish M-Score-2.85A
Grade A: SafeEarnings manipulation risk. < -2.22 Safe
FCF Conversion123.2%A
Grade A: StrongFCF / Net Income
Margin Stability6.2%A
Grade A: StableEBIT margin std deviation. Lower = stable
Capex / Revenue2.7%A
Grade A: Asset-lightTTM CapEx / TTM Revenue — high % = capital-hungry business
Asset Turnover0.54xC
Grade C: AverageRevenue / Total Assets (Finnhub) — how efficiently the asset base generates sales
Insider Transactions
SEC Form 4 · 8 recordsP/S codes are the directional signal; grants, option exercises and tax withholding carry none. Form 4 doesn't flag 10b5-1 plans — scheduled sales may appear within open-market sells.
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Gallman Cari Filed | Gallman Cari | Option exercise | -4559 | |
Gallman Cari Filed | Gallman Cari | Tax withholding | -2332 | |
Gallman Cari Filed | Gallman Cari | Option exercise | +4.6K | |
Samuels Theodore R. II Filed | Samuels Theodore R. II | Grant / award | +821 | |
McMullen Michael R. Filed | McMullen Michael R. | Grant / award | +561 |
Show 3 more filingsShow fewer filings
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Rice Derica W Filed | Rice Derica W | Grant / award | +621 | |
Arduini Peter J Filed | Arduini Peter J | Grant / award | +561 | |
YALE PHYLLIS R Filed | YALE PHYLLIS R | Grant / award | +561 |
Option exercise (M) rows report a derivative leg, not an open-market sale — a paired negative entry is the option position being consumed.
More metrics — Moat, Per Share, Balance Sheet, MarketHide additional metrics
Moat
63BROIC >12% Years6/10 yrsC
Grade C: ModerateShare of completed fiscal years with ROIC > 12% — measures multi-year capital-return durability
Gross Margin (Med.)71.7%A
Grade A: DurableMedian annual gross margin across available fiscal years — pricing-power durability
FCF-Positive Years10/10 yrsA
Grade A: DurableShare of completed fiscal years with positive free cash flow
Net Margin Floor-21.2%D
Grade D: WeakWeakest annual net margin across completed fiscal years — recession/downcycle resilience
Per Share
EPS (TTM)$4.54
Own TTM net income / shares — same earnings basis as P/E
Cash / Share$5.42
Cash & short-term investments per share (Finnhub)
Book Value / Share$10.92
Shareholders' equity per share (Finnhub). Negative = accumulated losses / heavy buybacks
Balance Sheet
Total Debt$45.11B
Total debt obligations (short + long term)
Cash & Equiv.$10.67B
Cash and short-term investments
Net Debt$34.44B
Total Debt minus Cash. Negative = Net Cash position
Total Equity$18.47B
Shareholders' equity (book value)
Asset / Liability1.26xC
Grade C: AdequateTotal Assets / Total Liabilities
Market
Market Cap$122.95B
Current Market Capitalization
Beta0.19B
Grade B: DefensivePrice sensitivity vs the market (Finnhub) — 1.0 moves with market, >1.2 amplifies swings
How grades work: each metric is graded A–D against fixed thresholds (tap a row for the meaning). Card grades map the pillar score to A+–E — a card grade is that pillar's own score, not an average of the rows shown.
Financials as of Jun 2026 · Ratio snapshot Oct 17, 2026
Key Insights: Bristol-Myers Squibb Co. (BMY)
BMY is down 1.35% at the last close. Bristol-Myers Squibb Co. meets 8 of 9 Piotroski F-Score criteria, placing its fundamental strength in the top tier of US-listed stocks. Altman Z-Score of 2.25 falls in the grey zone (1.81–2.99) — financial distress is unlikely but not ruled out. Beneish M-Score of -2.85 suggests a low likelihood of earnings manipulation. Bristol-Myers Squibb Co. converts about 23% of revenue into free cash flow — strong cash generation.
- Takes ~3.0 years to repay net debt from free cash flow.
- Bristol-Myers Squibb Co. posted a net loss in 2 of 10 available completed fiscal years (2016–2025).
- At a valuation score of 90/100, BMY trades near the cheapest end of its own historical range (P/E 13.2).
- Return on equity of 50.2% is well above the market average.
- The stock currently yields 6.0% in dividends.
See how BMY ranks on the Capex Tracker — top 50 capital spenders compared.
Recent Market Moves
See all BMY moves →| Date | Session | Price | Move | Z-Score |
|---|---|---|---|---|
| Oct 14 | Regular | 59.14 | +4.35% | 3.41 |
| Oct 14 | After-hours | 59.63 | +5.22% | 3.99 |
| Oct 12 | Pre-market | 60.92 | +3.04% | 2.59 |
| Oct 5 | Regular | 58.74 | -3.95% | -2.98 |
| Oct 5 | After-hours | 58.80 | -3.84% | -2.89 |
Frequently Asked Questions about BMY
What is the current Bristol-Myers Squibb Co. (BMY) stock price?
BMY is trading at $59.75 at the last market close, down 1.35% on the session. PreMarketPrice tracks BMY pre-market, intraday and after-hours prices.
Is BMY stock a buy right now?
PreMarketPrice's quantitative model rates Bristol-Myers Squibb Co.'s financial health at 53/100. This is a data-driven snapshot of fundamentals, not investment advice.
Is BMY stock overvalued?
Bristol-Myers Squibb Co. trades at a trailing P/E of 13.2 and our valuation score rates it 90/100 (higher = cheaper vs. its own history). See the Valuation History and Key Metrics sections for forward P/E, EV/EBITDA and PEG context.
When does Bristol-Myers Squibb Co. report earnings?
No confirmed earnings date is currently scheduled for BMY. The Earnings section lists recent reports and updates as dates are announced.
What sector does Bristol-Myers Squibb Co. operate in?
Bristol-Myers Squibb Co. operates in the Healthcare sector, within the Drug Manufacturers - General industry. The Related Stocks section lists sector peers for comparison.
What does Bristol-Myers Squibb Co. do?
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders.
About Bristol-Myers Squibb Co. (BMY) Stock
Bristol-Myers Squibb Co. (BMY) is a US-listed stock operating in the Healthcare sector, specifically the Drug Manufacturers - General industry. As of the latest update, Bristol-Myers Squibb Co. is trading at $59.75, down 1.35% on the day with a market capitalization of $123.0 billion. The financial health score for BMY is 53/100, which indicates moderate financial strength based on profitability, leverage, liquidity, and growth metrics. This page provides real-time pre-market pricing, earnings calendar, financial health analysis, and valuation metrics for BMY stock.
BMY Stock Analysis & Key Metrics
On PreMarketPrice, you can track Bristol-Myers Squibb Co. (BMY) across multiple dimensions:
- Pre-market price & movement: Real-time BMY stock price with percentage change, updated continuously during pre-market and regular trading hours.
- Valuation & P/E history: Historical P/E, P/S, and P/B ratios for BMY with trend analysis and normalized valuation multiples.
- Financial statements: Revenue, net income, assets, liabilities, and equity for Bristol-Myers Squibb Co. across multiple reporting periods.
- Financial health score: A composite score of 53/100 based on Altman Z-Score, Piotroski F-Score, profitability, and leverage metrics for BMY.
- Sector peers: Compare BMY against 5 other healthcare stocks on key financial metrics.
Is BMY a Good Stock to Buy?
This page provides data-driven analysis to help you evaluate Bristol-Myers Squibb Co. (BMY) as an investment. The financial health score of 53/100 suggests moderate financial fundamentals. Valuation metrics show whether the stock is trading above or below its historical average.However, this is not financial advice — always do your own research before investing.
Data on this page is sourced from real-time market feeds, Polygon.io, and Finnhub.Bristol-Myers Squibb Co. (BMY) trades on NYSE/NASDAQ. Pre-market trading occurs 4:00 AM – 9:30 AM ET. Regular market hours are 9:30 AM – 4:00 PM ET.